Conmed (CNMD) Up 7.1% Since Last Earnings Report: Can It Continue?
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research8/28/2026Positive
CNMD
CONMED CorporationNYSEHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$1.48B
P/E Ratio
26.66
EPS
$1.85
Beta
0.91
52W High
$54.02
52W Low
$31.44
50-Day MA
$44.71
200-Day MA
$40.47
Dividend Yield
0.40%
Profit Margin
4.12%
Forward P/E
27.17
PEG Ratio
1.84
About CONMED Corporation
CONMED Corporation, a medical technology company, develops, manufactures and sells surgical devices and related equipment for minimally invasive procedures worldwide. The company is headquartered in Largo, Florida.
Fundamentals
| Revenue (TTM) | $1.37B |
| Gross Profit (TTM) | $762.31M |
| EBITDA | $227.46M |
| Operating Margin | 14.60% |
| Return on Equity | 5.53% |
| Return on Assets | 4.14% |
| Revenue/Share (TTM) | $44.70 |
| Book Value | $34.73 |
| Price-to-Book | 1.42 |
| Price-to-Sales (TTM) | 1.08 |
| EV/Revenue | 1.66 |
| EV/EBITDA | 12.08 |
| Quarterly Earnings Growth (YoY) | 11.20% |
| Quarterly Revenue Growth (YoY) | 0.30% |
| Shares Outstanding | $29.95M |
| Float | $29.66M |
| % Insiders | 0.43% |
| % Institutions | 116.69% |
Historical Volatility
HV 10-Day
11.62%
HV 20-Day
19.95%
HV 30-Day
46.76%
HV 60-Day
56.36%
HV Rank
76.2%
Volatility is currently contracting
Analyst Ratings
Consensus ($45.50 target)
5
Hold1
Strong SellLatest News
CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its participation in the Wells Fargo 21st Annual Healthcare Conference, which is being held September 8-10, 2026 at the Encore Boston Harbor in Everett, MA. Management will participate in a fireside chat on Wednesday, September 9th at 1:30 p.m. Eastern Time. A live audio webcast of the fireside chat will be accessible under the “Events” section of the company's investor relations website: https://www.conmed.com/en/inv.
Business Wire8/26/2026Neutral
CONMED Corporation: Organic Growth Is Masked By Divestitures
Conmed's headline growth appeared flat at $343 million in the last quarter, but organic growth actually increased by 6%, with the leading segment being the orthopedic surgery business. Growth was offset by the divestiture of the GI business; as a result, growth metrics look poor with a quant rating of F and below the sector growth. When I adjust for organic growth, impressive profitability, and a buyback story, Conmed stock looks highly undervalued below the sector multiple. and I am rating it a buy.
Seeking Alpha8/18/2026Positive
CNMD Jumps 16% in a Month as Investors Assess Whether It Can Last
CNMD's 16% monthly rally is backed by stronger growth, margin gains and raised earnings guidance, but cash-flow and execution risks remain.
Zacks Investment Research8/17/2026Positive
Can CONMED's Raised 2026 EPS Outlook Reinforce Its Growth Momentum?
CONMED raised its 2026 adjusted EPS outlook after a strong second quarter, but slower organic growth and higher financing costs keep the setup mixed.
Zacks Investment Research8/17/2026Neutral
Is CNMD a Buy Now as Low Valuation Meets Persistent Execution Risk?
CNMD's low valuation and improved earnings outlook strengthen its appeal, but cash-flow pressure and execution risks keep the buy case measured.
Zacks Investment Research8/17/2026Positive
Here's Why You Should Retain CONMED Stock in Your Portfolio Now
CONMED's growth outlook is supported by Buffalo Filter, BioBrace and organic momentum, though slower AirSeal growth and tariffs remain key risks.
Zacks Investment Research8/17/2026Neutral
CONMED Q2 Earnings and Revenues Beat Estimates, Gross Margin Expands
CNMD's Q2 earnings and revenues beat estimates, while margin growth and solid international sales support a higher 2026 EPS outlook.
Zacks Investment Research7/30/2026Positive
CONMED Corporation (CNMD) Q2 2026 Earnings Call Transcript
CONMED Corporation (CNMD) Q2 2026 Earnings Call Transcript
Seeking Alpha7/30/2026Neutral
CONMED Q2 Earnings Call Highlights
CONMED NYSE: CNMD reported second-quarter 2026 net sales of $343.5 million, up 0.3% on a reported basis but down 0.5% in constant currency. Organic sales, which exclude the company's exited gastroenterology product offerings, rose 6% year over year and modestly exceeded management's expectations.
MarketBeat7/30/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CNMD and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/7/2026